Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischaemic optic neuropathy.

05:48 EDT 1st August 2014 | BioPortfolio

Summary of "Single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischaemic optic neuropathy."

Background:  The aim was to evaluate the effect of a single intravitreal ranibizumab injection in eyes with non-arteritic anterior ischaemic optic neuropathy. Methods:  Four eyes of four patients comprised the study group. In addition to a standard ocular examination, visual field testing and retinal nerve fibre layer thickness analysis were performed prior to injection and one and three months after the injection. Results:  Mean time between visual loss and the intravitreal injection was 7.8 days (range, 2-15 days). The mean age of patients was 58.2 years (range, 45-63 years). After a single dose of ranibizumab injection, all patients experienced a visual gain. Mean visual acuity (VA) was 1.15 ± 0.26 logMar before the injection and improved to 0.37 ± 0.09 logMar at the third post-injection month. The mean retinal nerve fibre layer thickness measured with spectral domain optical coherence tomography significantly decreased after the injection in all eyes. No complication related to the injections was observed during the following three months. Conclusion:  Intravitreal ranibizumab injection may be a treatment option in eyes with non-arteritic anterior ischaemic optic neuropathy and a short disease history.

Affiliation

Dokuz Eylul University, Department of Ophthalmology, Izmir, Turkey E-mail: osman.saatci@deu.edu.tr.

Journal Details

This article was published in the following journal.

Name: Clinical & experimental optometry : journal of the Australian Optometrical Association
ISSN: 1444-0938
Pages:

Links

PubMed Articles [15185 Associated PubMed Articles listed on BioPortfolio]

Intraocular Pharmacokinetics of Ranibizumab in Vitrectomized versus Non-vitrectomized Eyes.

Purpose: To analyze the intraocular pharmacokinetic properties of intravitreally injected ranibizumab in vitrectomized and non-vitrectomized rabbit eyes. Methods: Twenty-five-gauge pars plana vitrecto...

Müller cells and microglia of the mouse eye react throughout the entire retina in response to the procedure of an intravitreal injection.

The animal model of N-methyl-D-aspartate (NMDA)-induced excitotoxic damage of retinal ganglion cells (RGC) is widely used to study the molecular mechanisms of RGC death and/or its prevention by neurop...

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration.

Purpose. To report our experiences in patients with age-related macular degeneration (AMD) treated initially with intravitreal ranibizumab and then switched to bevacizumab. Methods. We retrospectively...

Clinical efficacy of intravitreal ranibizumab in early and mid-idiopathic choroidal neovascularization.

Background. To compare visual outcomes and spectral-domain optical coherence tomography results following intravitreal ranibizumab treatment for early and mid-idiopathic choroidal neovascularization (...

One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.

To compare the 1-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy (RF-PDT) to intravitreal ranibizumab (IVR) alone for eyes with polypoidal choroidal vasculo...

Clinical Trials [4700 Associated Clinical Trials listed on BioPortfolio]

Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)

To evaluate the fluorescein angiographic and visual acuity effects of a single intravitreal injection of ranibizumab for the management of persistent new vessels associated with diabetic r...

Intravitreal Ranibizumab for VH Due to PDR (N)

This study is being conducted to determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eye...

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasm...

Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema

The purpose of the study is to find out which is a better treatment for diabetic macular edema (DME): laser alone, laser combined with an intravitreal injection of triamcinolone, laser co...

Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration

To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab and ranibizumab in patients with choroidal neovascularization secondary to age-rela...

Medical and Biotech [MESH] Definitions

Hemorrhagic necrosis that was first demonstrated in rabbits with a two-step reaction, an initial local (intradermal) or general (intravenous) injection of a priming endotoxin (ENDOTOXINS) followed by a second intravenous endotoxin injection (provoking agent) 24 h later. The acute inflammation damages the small blood vessels. The following intravascular coagulation leads to capillary and venous THROMBOSIS and NECROSIS. Shwartzman phenomenon can also occur in other species with a single injection of a provoking agent, and during infections or pregnancy. Its susceptibility depends on the status of IMMUNE SYSTEM, coagulation, FIBRINOLYSIS, and blood flow.

The administration of substances into the VITREOUS BODY of the eye with a hypodermic syringe.

Acute conjunctival inflammation in the newborn, usually caused by maternal gonococcal infection. The causative agent is NEISSERIA GONORRHOEAE. The baby's eyes are contaminated during passage through the birth canal.

Gases that irritate the eyes, throat, or skin. Severe lacrimation develops upon irritation of the eyes.

Partial or complete loss of vision in one half of the visual field(s) of one or both eyes. Subtypes include altitudinal hemianopsia, characterized by a visual defect above or below the horizontal meridian of the visual field. Homonymous hemianopsia refers to a visual defect that affects both eyes equally, and occurs either to the left or right of the midline of the visual field. Binasal hemianopsia consists of loss of vision in the nasal hemifields of both eyes. Bitemporal hemianopsia is the bilateral loss of vision in the temporal fields. Quadrantanopsia refers to loss of vision in one quarter of the visual field in one or both eyes.

Search BioPortfolio: